Yazen

Yazen is a digital healthcare company that provides medically supervised weight‑loss treatment combining modern medications, personalized lifestyle coaching, and continuous digital follow‑up to treat obesity across several European markets[5][1].

High-Level Overview

Yazen is a digital healthcare provider focused on obesity care that delivers a combined medical and behavioral treatment program through an app and remote clinical team[5][1]. The company pairs licensed physicians with coaches, dietitians, psychologists and trainers to create individualized plans that use evidence‑based medicines plus lifestyle support; it reports over 40,000 patients treated to date and more than 360 tonnes of weight lost across its patient base[1]. Yazen has grown rapidly across Europe—operating in Sweden, Norway, Denmark, the Netherlands, the UK, Germany and Spain—and recently scaled headcount and revenue substantially while being ranked the second fastest‑growing startup in Europe by Sifted’s 2025 list[1][5].

Origin Story

Yazen was founded in 2021 by entrepreneurs with prior experience building digital health services (the founders previously launched services such as MinDoktor and Blodtrycksdoktorn), and it is headquartered in Lund, Sweden[3][5]. The idea emerged from combining clinical obesity expertise with tech‑enabled remote delivery to address long‑term chronic care needs for patients with overweight and obesity; early traction included rapid user growth and clinical scale—reaching tens of thousands of patients within a few years—and expansion into multiple European markets[1][3].

Core Differentiators

• Clinically led, multidisciplinary care model: Licensed physicians plus YazenCoaches, dietitians, psychologists and personal trainers deliver coordinated, long‑term obesity treatment rather than one‑off weight‑loss interventions[5][1].
• Medication + lifestyle integration: The program explicitly combines *modern medicines* with behavioral and lifestyle changes and continuous digital follow‑up, positioning it as a medical treatment pathway for obesity (a chronic disease) rather than a pure wellness app[5][1].
• Rapid European scale and outcomes data: Public reporting highlights >40,000 treated patients and strong aggregate weight‑loss outcomes (over 360 tonnes of weight lost), which supports claims of clinical impact and commercial traction[1].
• Product accessibility and convenience: App‑based delivery with 24/7 availability and remote clinical access lowers barriers for patients across markets[5].
• Proven growth & recognition: Significant revenue and headcount acceleration and third‑party rankings (Sifted) underline market momentum and investor confidence[1].

Role in the Broader Tech Landscape

• Riding the digital therapeutics and virtual care trend: Yazen sits at the intersection of telemedicine, digital therapeutics and value‑based chronic care—categories that have attracted capital and regulatory attention as healthcare systems seek scalable, outcomes‑focused solutions[5][1].
• Timing: Rising prevalence and clinical recognition of obesity as a chronic disease increases demand for long‑term, medically supervised solutions; simultaneously, acceptance of GLP‑1 and other pharmacotherapies has grown, making integrated digital delivery attractive[1][5].
• Market forces in its favor: Workforce shortages, need for remote care, and payer interest in cost‑effective chronic disease management create adoption tailwinds for scalable digital clinical providers. Yazen’s cross‑market expansion positions it to aggregate real‑world outcomes and negotiate with employers or payers.
• Ecosystem influence: By combining medicine, coaching and continuous monitoring at scale, Yazen helps normalize long‑term pharmacologic plus behavioral obesity treatment in Europe and may push competitors and health systems toward outcome‑driven, hybrid care models[1][5].

Quick Take & Future Outlook

Yazen has established a differentiated, medically oriented digital obesity clinic and demonstrated rapid scale and measurable outcomes across multiple European countries—making it a leading player in digital obesity care[1][5]. Near term, expect continued geographic expansion, product refinement (deeper care pathways, tighter integration with primary care and payers), and efforts to commercialize relationships with employers and health systems as evidence accumulates. Key trends that will shape Yazen’s trajectory include regulatory stance on obesity medications, reimbursement models for long‑term digital care, and competition from other digital therapeutics and clinic networks integrating GLP‑1 therapies[1][5]. If Yazen sustains clinical outcomes and converts scale into repeatable payer or employer contracts, it could become a standard channel for accessible, long‑term obesity treatment across Europe—fulfilling its stated aim to be Europe’s leading digital obesity care provider[1][5].

Sources: Yazen corporate site and company news; Almaz Capital portfolio description; The Hub company profile[5][2][3][1].